Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 08/25/11 → 01/6/17 |
Funding
- Pfizer Incorporated: $117,424.64
A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer Following Progression After, or Intolerance to, At Least One Prior Chemotherapy
- Keresztes, Roger (PI)
- Gabig, Theodore (CoPI)
Project: Research